Skip to main content
Evidence Snapshot

D(3) dopamine receptor

CHEMBL234 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T16:32:22Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL234
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats D(3) dopamine receptor as ChEMBL target CHEMBL234, mapped to UniProt P35462. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
D(3) dopamine receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL234
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P35462
D(3) dopamine receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why D(3) dopamine receptor matters

As of 2026-09-13

D(3) dopamine receptor is reviewed as D(3) dopamine receptor (UniProt P35462); D(3) dopamine receptor shows approved-linked disease relevance led by schizophrenia. 5 more disease programs remain visible in the same review block.; 6 linked drugs keep this evidence frame grounded.; the current evidence base includes 194 approved drugs, 10185 compounds, and 1242 assays, with lead potency reaching pChEMBL 10.9.

Disease context
schizophrenia

D(3) dopamine receptor shows approved-linked disease relevance led by schizophrenia. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ABT-925, BLONANSERIN, CARIPRAZINE HYDROCHLORIDE.

Start review with schizophrenia because it currently carries approved-linked support. Linked drugs include ABT-925, BLONANSERIN, CARIPRAZINE HYDROCHLORIDE, CHLORPROTHIXENE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 6 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 194 approved drugs, 10185 compounds, and 1242 assays for this target. The dominant activity type is KI. CHEMBL5841759 is the current potency anchor at pChEMBL 10.9.

Use CHEMBL5841759 as the tractability anchor when discussing potency (pChEMBL 10.9).

Activity source · ChEMBL 36 via Core Engine
194 approved pChEMBL 10.9
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why D(3) dopamine receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P35462, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why schizophrenia is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

10185
Total Compounds
1242
Total Assays
194
Approved Drugs
IC50: 1303.0, KI: 9585.0, EC50: 932.0, KD: 28.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5841759
 10.9 Ki —
No preferred name
CHEMBL5802711
 10.8 Ki —
No preferred name
CHEMBL5918571
 10.8 Ki —
No preferred name
CHEMBL5924177
 10.8 Ki —
No preferred name
CHEMBL349426
 10.7 Ki —

Approved Drugs

Structure Compound First Approval
BREXPIPRAZOLE
CHEMBL2105760
 2015
CARIPRAZINE HYDROCHLORIDE
CHEMBL2024517
 2015
CARIPRAZINE
CHEMBL2028019
 2015
VILAZODONE HYDROCHLORIDE
CHEMBL1615374
 2011
MACITENTAN
CHEMBL2103873
 2010
ASENAPINE
CHEMBL3187365
 2009
SILODOSIN
CHEMBL24778
 2008
PALIPERIDONE
CHEMBL1621
 2006
ROTIGOTINE
CHEMBL1303
 2006
CINACALCET HYDROCHLORIDE
CHEMBL1200776
 2004
TEGASEROD MALEATE
CHEMBL1516474
 2002
ARIPIPRAZOLE
CHEMBL1112
 2002
DESLORATADINE
CHEMBL1172
 2001
ZIPRASIDONE
CHEMBL708
 2001
APOMORPHINE
CHEMBL53
 2001
RABEPRAZOLE
CHEMBL1219
 1999
KETOTIFEN
CHEMBL534
 1999
KETOTIFEN FUMARATE
CHEMBL1633
 1999
PRAMIPEXOLE DIHYDROCHLORIDE
CHEMBL3182733
 1997
QUETIAPINE
CHEMBL716
 1997
PRAMIPEXOLE
CHEMBL301265
 1997
TAMSULOSIN
CHEMBL836
 1997
RALOXIFENE
CHEMBL81
 1997
ROPINIROLE
CHEMBL589
 1997
OLANZAPINE
CHEMBL715
 1996
SERTINDOLE
CHEMBL12713
 1996
AZELASTINE HYDROCHLORIDE
CHEMBL1200809
 1996
CARVEDILOL
CHEMBL723
 1995
AMIFOSTINE
CHEMBL1006
 1995
NEFAZODONE HYDROCHLORIDE
CHEMBL1200492
 1994
CISAPRIDE
CHEMBL1729
 1993
RISPERIDONE
CHEMBL85
 1993
EBASTINE
CHEMBL305660
 1990
CLOMIPRAMINE
CHEMBL415
 1989
CLOZAPINE
CHEMBL42
 1989
ASTEMIZOLE
CHEMBL296419
 1988
PERGOLIDE
CHEMBL531
 1988
OXICONAZOLE
CHEMBL1262
 1988
AMISULPRIDE
CHEMBL243712
 1986
BUSPIRONE
CHEMBL49
 1986
HALOPERIDOL DECANOATE
CHEMBL1200986
 1986
DRONABINOL
CHEMBL465
 1985
AMIODARONE
CHEMBL633
 1985
TERFENADINE
CHEMBL17157
 1985
PIMOZIDE
CHEMBL1423
 1984
HALOPROGIN
CHEMBL1289
 1982
PINDOLOL
CHEMBL500
 1982
GENTIAN VIOLET
CHEMBL64894
 1982
VERAPAMIL
CHEMBL6966
 1981
MAPROTILINE
CHEMBL21731
 1980
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T16:32:22Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL234